CGH
SRPT icon

Crossmark Global Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Crossmark Global Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,180
Closed -$458K – 1366
2025
Q1 		$458K Buy
7,180
+153
+2% +$16.1K 0.01% 909
2024
Q4 		$854K Sell
7,027
-134
-2% -$16.4K 0.02% 625
2024
Q3 		$894K Buy
7,161
+994
+16% +$137K 0.02% 648
2024
Q2 		$975K Buy
+6,167
New +$792K 0.02% 592
2018
Q4 		– Sell
-1,520
Closed -$245K – 1539
2018
Q3 		$245K Buy
+1,520
New +$208K 0.01% 1442

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Crossmark Global Holdings's SRPT Position: Q2 2025 in Review

Crossmark Global Holdings sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 7,180 shares — an estimated $458K sold.

Crossmark Global Holdings first reported a position in SRPT in Q3 2018 and held it in 5 quarters. The position peaked at $975K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Crossmark Global Holdings reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Crossmark Global Holdings sold 7,180 Sarepta Therapeutics shares in Q2 2025, an estimated $458K.
  • Crossmark Global Holdings first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 5 quarters.
  • Crossmark Global Holdings's Sarepta Therapeutics position peaked at $975K in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Crossmark Global Holdings's 13F filing for Q2 2025, filed 8 Aug 2025.